HC Wainwright Analysts Increase Earnings Estimates for FULC

Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Analysts at HC Wainwright raised their FY2024 earnings per share (EPS) estimates for shares of Fulcrum Therapeutics in a research note issued on Thursday, November 14th. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of ($0.12) for the year, up from their previous forecast of ($0.15). HC Wainwright currently has a "Neutral" rating and a $4.00 target price on the stock. The consensus estimate for Fulcrum Therapeutics' current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Fulcrum Therapeutics' Q4 2024 earnings at ($0.23) EPS, Q1 2025 earnings at ($0.22) EPS, Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.81) EPS, FY2026 earnings at ($1.00) EPS, FY2027 earnings at ($0.99) EPS and FY2028 earnings at ($0.84) EPS.

Several other equities research analysts have also issued reports on the company. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Thursday. Cantor Fitzgerald lowered Fulcrum Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Thursday, September 12th. Leerink Partnrs lowered Fulcrum Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Thursday, September 12th. Bank of America lowered Fulcrum Therapeutics from a "neutral" rating to an "underperform" rating and decreased their price target for the stock from $10.00 to $2.00 in a research note on Thursday, September 12th. Finally, Leerink Partners reissued a "market perform" rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a research note on Thursday, September 12th. One analyst has rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and an average target price of $9.33.

Fulcrum Therapeutics Price Performance

Shares of NASDAQ:FULC traded up $0.02 during trading on Monday, hitting $3.03. The company had a trading volume of 2,355,184 shares, compared to its average volume of 996,355. The stock has a market cap of $163.44 million, a price-to-earnings ratio of -9.77 and a beta of 2.24. Fulcrum Therapeutics has a one year low of $2.87 and a one year high of $13.70. The company has a fifty day simple moving average of $3.75 and a two-hundred day simple moving average of $6.47.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in Fulcrum Therapeutics by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 2,538,665 shares of the company's stock worth $23,965,000 after purchasing an additional 18,681 shares during the period. State Street Corp increased its holdings in Fulcrum Therapeutics by 61.4% during the 3rd quarter. State Street Corp now owns 1,680,229 shares of the company's stock worth $5,998,000 after purchasing an additional 638,955 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Fulcrum Therapeutics by 13.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,480,926 shares of the company's stock valued at $9,182,000 after acquiring an additional 176,114 shares during the period. Geode Capital Management LLC increased its holdings in shares of Fulcrum Therapeutics by 1.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,320,862 shares of the company's stock valued at $4,716,000 after acquiring an additional 13,485 shares during the period. Finally, Braidwell LP purchased a new position in shares of Fulcrum Therapeutics in the 3rd quarter valued at $3,817,000. 89.83% of the stock is currently owned by hedge funds and other institutional investors.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.